Highest-materiality recent filing
Canton Strategic Holdings authorizes $50M share repurchase program
Board approved up to $50M in common stock repurchases on June 11, 2026; press release June 16.
Canton Strategic Holdings reports FY2025 net loss of $35.9M, holds $501.8M in Canton Coin
Net loss of $35.9M ($1.12 per diluted share); accumulated deficit $72.8M; no revenue recognized.
Canton Strategic Holdings CEO Mark Wendland elected to Canton Foundation Board
Mark Wendland, Chairman and CEO, elected to Canton Foundation Board of Directors.
Canton Strategic Holdings enters $300M ATM sales agreement with Clear Street and Virtu
Aggregate gross sales price of $300,000,000 available for issuance under amended and restated sales agreement.
Corporate name changed to Canton Strategic Holdings, Inc.; new NASDAQ ticker CNTN effective Feb. 18, 2026.
Tharimmune appoints Angela Radkowski as COO and CEO Mark Wendland as Chairman
Angela Radkowski appointed COO effective Feb 5, 2026; previously Operations Strategy Lead at DRW and Citadel.
Tharimmune shareholders approve board election, share issuances and 7M share plan increase
Shareholders elected Jill Sommers and William Wiley to the board with strong vote majorities (Sommers 19.95M for, Wiley 20.05M for).
Tharimmune approves expanded role as Super Validator on Canton Network
Tharimmune (NASDAQ: THAR) approved to operate a Super Validator on the Canton Network.
Tharimmune closes $55M registered direct offering of 1.8M shares and pre-funded warrants
Gross proceeds ~$55M from 1,800,000 shares at $2.92 and pre-funded warrants for 17M shares at $2.9199.
Tharimmune prices $55M offering: 1.8M shares at $2.92, 17M pre-funded warrants
Offering totals $55M; includes 1,800,000 shares at $2.92 per share.
Tharimmune receives Nasdaq noncompliance notice for board independence; plans cure at Jan 30 meeting
Nasdaq notified Tharimmune on Jan 9, 2026 of noncompliance with Listing Rule 5605 (majority independent directors) following resignations of Nancy Davis and Sanam Parikh effective Nov 6, 2025.
Tharimmune appoints Jacob Asbury as CFO, replaces interim CFO Sireesh Appajosyula
Jacob Asbury appointed CFO effective December 10, 2025; base salary $300,000/year plus annual target bonus of $100,000.
Tharimmune Appoints Sireesh Appajosyula as Interim CFO
On November 7, 2025, Tharimmune's Board appointed Sireesh Appajosyula as interim Chief Financial Officer.
Closed $545M private placement at $3.075/share with DRW, Liberty City Ventures, others; proceeds to acquire Canton Coin and support Canton Network.
Tharimmune raises $545M in PIPE, appoints new CEO, pivots to crypto treasury
Issued 25,966,048 shares and 151,456,115 pre-funded warrants at $3.075/share, raising ~$545M gross.
Tharimmune launches private placement of stock and pre-funded warrants at $3.075 per share
Offering includes shares of common stock and pre-funded warrants for both cash and cryptocurrency consideration.
Tharimmune raises ~$540M in private placement for Canton Coin treasury; appoints Wendland CEO of DAT
Gross proceeds ~$540M from sale of common stock/pre-funded warrants at $3.075/share; closing expected Nov 6, 2025.
Tharimmune increases authorized common stock from 250M to 1B shares
Filed Certificate of Amendment with Delaware Secretary of State on October 10, 2025.
Tharimmune stockholders approve 4x authorized share increase and expanded equity plan
Authorized common shares may increase from 250M to 500M–1B; board has discretion until Oct 9, 2026.
Tharimmune amends warrants for 3.4M shares to be immediately exercisable
Entered warrant amendment with holders of warrants covering 3,408,110 common shares.
Tharimmune increases CEO and Chairman base salary to $385,000, triples change-of-control severance
CEO Sireesh Appajosyula and Executive Chairman Vincent LoPriore base salary increased by $100,000 to $385,000.
Tharimmune regains Nasdaq equity compliance after raises totaling $7.05M
Received Nasdaq deficiency notice Apr 1, 2025 for stockholders' equity below $2.5M minimum.
Tharimmune regains Nasdaq compliance with $6.9M equity as of Aug 31, 2025
Nasdaq letter dated Sept 5, 2025 confirms stockholders' equity of $6,876,335.
Tharimmune enters securities purchase agreement for $5.35 million registered direct offering
Offering consists of 1,188,888 shares of common stock (or common stock equivalents) at $4.50 per share.
Tharimmune raises $5.35M in registered direct offering at $4.50/share
Offering of 1,188,888 shares or common stock equivalents at $4.50 per share.
Tharimmune appoints Nancy Davis to board of directors
Nancy Davis, founder of Race to Erase MS and Cure Addiction Now, joins Tharimmune board effective August 4, 2025.
Tharimmune raises $1.225M in private placement of common stock and warrants
Gross proceeds of $1,225,003 from sale of 641,190 common shares, 103,490 pre-funded warrants, and 744,680 common warrants.
Tharimmune prices $1.74M unit offering of common stock and warrants at $1.786/unit
Offering: 414,331 shares, 559,910 pre-funded warrants, and 974,241 common warrants (exercise $1.66).
Director Kelly Anderson resigns from Tharimmune Board
Kelly Anderson resigned from the Board effective June 22, 2025 for personal reasons.
Tharimmune raises ~$2.5M in private placement of equity and warrants
Gross proceeds ~$2.5M from 1,551,351 shares, pre-funded warrants for 137,838 shares at $0.001.
Tharimmune CFO Don Kim resigns effective June 10, 2025; no replacement named
CFO Don Kim resigned for personal reasons, effective immediately on June 10, 2025.
Tharimmune CEO resigns; appoints Sireesh Appajosyula as new CEO, adds director
CEO Randy Milby resigned for personal reasons; receives $133,500 settlement and accelerated vesting of unvested options, contingent on $3M+ financing.
Tharimmune shareholders elect directors, ratify auditor, approve equity plan at annual meeting
All seven director nominees elected; Randy Milby received 480,332 for, 296,465 abstain, 352,661 broker non-votes.
Tharimmune appoints Vincent LoPriore as Executive Chairman, replacing Randy Milby
Vincent LoPriore, a current director, named Executive Chairman effective May 9, 2025.
Tharimmune appoints Clay Kahler and Gary Stetz to Board, expanding to 9 members
Board size increased from 8 to 9 on April 28, 2025.
Two directors retire from Tharimmune board; not seeking re-election at June 10 annual meeting
Leonard Mazur and Lynne Bui, MD will retire from the Board effective June 10, 2025.
Tharimmune appoints Vincent LoPriore to Board of Directors
Board size increased to seven members on April 9, 2025.
Tharimmune receives Nasdaq delisting notice for insufficient stockholders' equity
Nasdaq notified Tharimmune on April 1, 2025, that stockholders' equity of $1,307,642 falls below the $2,500,000 minimum required by Listing Rule 5550(b)(1).
Tharimmune announces CFO transition: Hess to depart March 26, Kim effective March 27
CFO Thomas Hess resigned effective March 26, 2025; no disagreement with company operations or policies.
Tharimmune raises $2.02M in private placement for TH104 development
Gross proceeds of ~$2.02M from issuance of 961,446 common shares (or equivalents) and warrants for 480,723 shares at $2.10 per unit.
Tharimmune appoints board member, terminates Intract Pharma merger LOI
Board increased to six members; Sanam Parikh appointed as director effective November 20, 2024.
Tharimmune signs nonbinding LOI to merge with Intract Pharma; 49% stake for Intract shareholders
Tharimmune and Intract Pharma entered nonbinding LOI; Tharimmune to acquire Intract for restricted stock.
Tharimmune licenses oral infliximab from Intract Pharma for global development
Exclusive global license (ex-South Korea) to INT-023/TH023, an oral anti-TNF-α monoclonal antibody infliximab.
Tharimmune announces $2.08M private placement; 659K shares & warrants at $3.16/unit
Gross proceeds of ~$2.08M from sale of 659,545 shares (or equivalents) and warrants to purchase 329,771 shares.
Tharimmune regains Nasdaq minimum bid price compliance
Received Nasdaq notice on June 11, 2024, confirming compliance with Listing Rule 5550(a)(2).
Tharimmune enters $0.0001 par value common stock ATM facility with Rodman & Renshaw
ATM Agreement allows Tharimmune to sell shares of common stock from time to time through Rodman & Renshaw as sales agent.
Tharimmune announces 1-for-15 reverse stock split to meet Nasdaq $1 minimum bid
1-for-15 reverse split effective after market close on May 24, 2024; post-split trading begins May 28, 2024.
Tharimmune shareholders approve reverse stock split (1:2 to 1:50) and equity plan
All 5 director nominees elected with vote totals ranging from 2,848,203 to 2,871,156 for.
Tharimmune amends bylaws to lower stockholder quorum from majority to one-third
Board approved amendment on March 7, 2024, amending Article II, Section 2.6 of bylaws.
Tharimmune reports 11.74M shares outstanding as of Feb 8, 2024
Share count of 11,739,676 common shares issued and outstanding as of February 8, 2024.
On June 22, 2025, Kelly Anderson resigned from the Board of Directors of Tharimmune, Inc. for personal reasons, effective immediately.
On June 10, 2025, Don Kim, Chief Financial Officer of Tharimmune, Inc. (the “Company”) resigned from his position as CFO for personal reasons, effective immediately.
Randy Milby pursuant to which he resigned for personal reasons from his positions as Chief Executive Officer and member of the Board of Directors, effective immediately.
the Board appointed Sireesh Appajosyula as the Company’s Chief Executive Officer, effective immediately.
the Board appointed James Gordon Liddy as a member of the Board, effective immediately.
Mr. LoPriore shall replace Randy Milby who served as Chairman of the Board.
On May 9, 2025, the Board of Directors (the “Board”) of Tharimmune, Inc. (the “Company”) appointed Vincent LoPriore, a director of the Company, as Executive Chairman of the Board, effective immediately.
On April 28, 2025, the Board of Directors (the “Board”) of Tharimmune, Inc. (the “Company”) increased the size of the Board to nine members and appointed each of Clay Kahler and Gary Stetz as members of the Board.
On April 28, 2025, the Board of Directors (the “Board”) of Tharimmune, Inc. (the “Company”) increased the size of the Board to nine members and appointed each of Clay Kahler and Gary Stetz as members of the Board.
appointed Vincent LoPriore as a member of the Board.
appointed Don Kim as Chief Financial Officer of the Company, effective as of March 27, 2025.
accepted the resignation of Thomas Hess as Chief Financial Officer of the Company, effective as of March 26, 2025.
Max materiality 1.00 · Median 0.60 · Most common event other_material